To test this hypothesis, we 1) confirmed the existence of a link between ACE2 and oxidative stress in vitro, 2) determined the impact of ACE2 deletion on ROS formation and autonomic function in vivo, and 3) assessed the potential of brain ACE2 gene therapy in the prevention of oxidative stress and dysautonomia. This evidence concerns the gene ACE2 and dysautonomia.